Trulance is an FDA-approved medication used for the treatment of chronic idiopathic constipation, and irritable bowel syndrome with constipation. Manufactured by Salix, Trulance with its active ingredient plecanatide helps to increase the fluid in your intestines which can help your stool pass through. This drug was first authorized for market use on 19 January, 2017.
Trulance has a total of 10 patents, 2 of which are expired. The last patent of Trulance is expected to expire on 5 June 2034. However, due to Para IV filings, drug patent challenges against Trulance can be filed from 19 January 2021. Therefore, we could potentially see Trulance generic alternatives in the market post-June 2034.
Trulance being a chronic idiopathic constipation treatment and irritable bowel syndrome with constipation treatment, it works by elevating the intracellular cGMP resulting in increased intestinal fluid and accelerated transit. Through this method, it aids in relieving constipation and easing bowel movements.
Trulance holds a few significant patents that impact its generic release. The most crucial patent expires on 5 June 2034. Therefore, the earliest possible date for a Trulance generic option could be after that date. Below are the details of the patent: